Informing New Perspectives in Antibiotic Development

Natureza^® carries out development of novel anti-infective agents. We have developed two agents that can help fulfill unmet healthcare needs for treatments against organisms with a high level of resistance to treatment agents. Together these represent a transformative breakthrough in the search for treatments showing no bacteria resistance.

Active against Candida auris, formulated as a topical agent or lyophilised in an enteric coated capsule. Also suitable for use as a surface disinfectant. Potent activity in in vitro trials, stable formulations. Target indications are treatment of Candida auris infections and surface disinfection in healthcare environments.
Active against Pseudomonas as single cells or in biofilms. Formulated as a lyophilised inhalable powder sized to penetrate to the alveoli in the lungs. This agent also shows anti-inflammatory activity in T cell models. Target indications are lung infections, early pulmonary fibrosis.

We are looking to license our patented agents for clinical development/co-development.

Characteristics of Natureza’s agents are:

No antibiotic resistance seen or developed on extended testing
Activity against WHO priority pathogens
Activity against multidrug resistant pathogens
- Candida auris
- Pseudomonas
- Carbapenem resistant Enterobacteriaceae
- MRSA, VISA
Anti inflammatory activity in formulation PY-1, more effective than cyclosporine

Natureza Patents New Antibiotic Agents

Natureza’s findings inform new perspectives in antibiotic development that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years, providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much-needed antibiotics.

Natureza Patents New Antibiotic Agents

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics.

This work is protected by US and foreign patents and patents pending.